289 related articles for article (PubMed ID: 23399899)
1. Atrophy, fibrosis, and increased PAX7-positive cells in pharyngeal muscles of oculopharyngeal muscular dystrophy patients.
Gidaro T; Negroni E; Perié S; Mirabella M; Lainé J; Lacau St Guily J; Butler-Browne G; Mouly V; Trollet C
J Neuropathol Exp Neurol; 2013 Mar; 72(3):234-43. PubMed ID: 23399899
[TBL] [Abstract][Full Text] [Related]
2. Premature proliferative arrest of cricopharyngeal myoblasts in oculo-pharyngeal muscular dystrophy: Therapeutic perspectives of autologous myoblast transplantation.
Périé S; Mamchaoui K; Mouly V; Blot S; Bouazza B; Thornell LE; St Guily JL; Butler-Browne G
Neuromuscul Disord; 2006 Nov; 16(11):770-81. PubMed ID: 17005403
[TBL] [Abstract][Full Text] [Related]
3. A de novo PABPN1 germline mutation in a patient with oculopharyngeal muscular dystrophy.
Gürtler N; Plasilova M; Podvinec M; Boesch N; Müller H; Heinimann K
Laryngoscope; 2006 Jan; 116(1):111-4. PubMed ID: 16481821
[TBL] [Abstract][Full Text] [Related]
4. [Oculopharyngeal muscular dystrophy: study of patients from seven Spanish families with different GCG expansions in PABP2 gene].
Pou Serradell A; Lloreta Trull J; Corominas Torres JM; Hammouda EH; Urtizberea JA; Richard P; Brais B
Neurologia; 2004 Jun; 19(5):239-47. PubMed ID: 15150706
[TBL] [Abstract][Full Text] [Related]
5. Nuclear speckles are involved in nuclear aggregation of PABPN1 and in the pathophysiology of oculopharyngeal muscular dystrophy.
Bengoechea R; Tapia O; Casafont I; Berciano J; Lafarga M; Berciano MT
Neurobiol Dis; 2012 Apr; 46(1):118-29. PubMed ID: 22249111
[TBL] [Abstract][Full Text] [Related]
6. Cytoplasmic targeting of mutant poly(A)-binding protein nuclear 1 suppresses protein aggregation and toxicity in oculopharyngeal muscular dystrophy.
Abu-Baker A; Laganiere S; Fan X; Laganiere J; Brais B; Rouleau GA
Traffic; 2005 Sep; 6(9):766-79. PubMed ID: 16101680
[TBL] [Abstract][Full Text] [Related]
7. Study of a Taiwanese family with oculopharyngeal muscular dystrophy.
Kuo HC; Chen CM; Lee-Chen GJ; Hu FJ; Chu CC; Liou CW; Huang CC
J Neurol Sci; 2009 Mar; 278(1-2):21-4. PubMed ID: 19101703
[TBL] [Abstract][Full Text] [Related]
8. Molecular and phenotypic characterization of a mouse model of oculopharyngeal muscular dystrophy reveals severe muscular atrophy restricted to fast glycolytic fibres.
Trollet C; Anvar SY; Venema A; Hargreaves IP; Foster K; Vignaud A; Ferry A; Negroni E; Hourde C; Baraibar MA; 't Hoen PA; Davies JE; Rubinsztein DC; Heales SJ; Mouly V; van der Maarel SM; Butler-Browne G; Raz V; Dickson G
Hum Mol Genet; 2010 Jun; 19(11):2191-207. PubMed ID: 20207626
[TBL] [Abstract][Full Text] [Related]
9. Myopathy phenotype in transgenic mice expressing mutated PABPN1 as a model of oculopharyngeal muscular dystrophy.
Hino H; Araki K; Uyama E; Takeya M; Araki M; Yoshinobu K; Miike K; Kawazoe Y; Maeda Y; Uchino M; Yamamura K
Hum Mol Genet; 2004 Jan; 13(2):181-90. PubMed ID: 14645203
[TBL] [Abstract][Full Text] [Related]
10. Oculopharyngeal muscular dystrophy: recent advances in the understanding of the molecular pathogenic mechanisms and treatment strategies.
Abu-Baker A; Rouleau GA
Biochim Biophys Acta; 2007 Feb; 1772(2):173-85. PubMed ID: 17110089
[TBL] [Abstract][Full Text] [Related]
11. Doxycycline attenuates and delays toxicity of the oculopharyngeal muscular dystrophy mutation in transgenic mice.
Davies JE; Wang L; Garcia-Oroz L; Cook LJ; Vacher C; O'Donovan DG; Rubinsztein DC
Nat Med; 2005 Jun; 11(6):672-7. PubMed ID: 15864313
[TBL] [Abstract][Full Text] [Related]
12. Animal model of oculopharyngeal muscular dystrophy.
Uyama E; Hino H; Araki K; Takeya M; Uchino M; Yamamura K
Acta Myol; 2005 Oct; 24(2):84-8. PubMed ID: 16550922
[TBL] [Abstract][Full Text] [Related]
13. Intranuclear Aggregates Precede Clinical Onset in Oculopharyngeal Muscular Dystrophy.
van der Sluijs BM; Raz V; Lammens M; van den Heuvel LP; Voermans NC; van Engelen BG
J Neuromuscul Dis; 2016 Mar; 3(1):101-109. PubMed ID: 27854203
[TBL] [Abstract][Full Text] [Related]
14. Analysis of growth factor expression in affected and unaffected muscles of oculo-pharyngeal muscular dystrophy (OPMD) patients: a pilot study.
Bouazza B; Kratassiouk G; Gjata B; Perie S; Lacau St Guily J; Butler-Browne GS; Svinartchouk F
Neuromuscul Disord; 2009 Mar; 19(3):199-206. PubMed ID: 19185491
[TBL] [Abstract][Full Text] [Related]
15. Oculopharyngeal muscular dystrophy (OPMD) due to a small duplication in the PABPN1 gene.
van der Sluijs BM; van Engelen BG; Hoefsloot LH
Hum Mutat; 2003 May; 21(5):553. PubMed ID: 12673802
[TBL] [Abstract][Full Text] [Related]
16. HnRNP A1 and A/B interaction with PABPN1 in oculopharyngeal muscular dystrophy.
Fan X; Messaed C; Dion P; Laganiere J; Brais B; Karpati G; Rouleau GA
Can J Neurol Sci; 2003 Aug; 30(3):244-51. PubMed ID: 12945950
[TBL] [Abstract][Full Text] [Related]
17. Progress in understanding the pathogenesis of oculopharyngeal muscular dystrophy.
Fan X; Rouleau GA
Can J Neurol Sci; 2003 Feb; 30(1):8-14. PubMed ID: 12619777
[TBL] [Abstract][Full Text] [Related]
18. [Preferential distal muscle involvement in case of oculopharyngeal muscular dystrophy with (GCG) 13 expansion].
Nakashima D; Nakajima H; Ishida S; Sugino M; Kimura F; Hanafusa T
Rinsho Shinkeigaku; 2003 Sep; 43(9):560-3. PubMed ID: 14727564
[TBL] [Abstract][Full Text] [Related]
19. PABPN1 overexpression leads to upregulation of genes encoding nuclear proteins that are sequestered in oculopharyngeal muscular dystrophy nuclear inclusions.
Corbeil-Girard LP; Klein AF; Sasseville AM; Lavoie H; Dicaire MJ; Saint-Denis A; Pagé M; Duranceau A; Codère F; Bouchard JP; Karpati G; Rouleau GA; Massie B; Langelier Y; Brais B
Neurobiol Dis; 2005 Apr; 18(3):551-67. PubMed ID: 15755682
[TBL] [Abstract][Full Text] [Related]
20. Cricopharyngeal myotomy in the treatment of oculopharyngeal muscular dystrophy.
Gómez-Torres A; Abrante Jiménez A; Rivas Infante E; Menoyo Bueno A; Tirado Zamora I; Esteban Ortega F
Acta Otorrinolaringol Esp; 2012; 63(6):465-9. PubMed ID: 22898142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
